- Brand names:
- Pharmaceutical Company:
- Condition/Indication: New vaccine - Prevention of coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2
- Meeting Date: December 2025
- Public Summary Document (PSD) May 2025 - December 2025 PBAC Meetings – (PDF 2.2MB)
- Public Summary Document (PSD) May 2025 - December 2025 PBAC Meetings – (Word 1.9MB)
Raxtozinameran (bnt162b2 mrna covid-19 vaccine) – December 2025
Raxtozinameran (bnt162b2 mrna covid-19 vaccine): Suspension for injection containing SARS-CoV-2 spike protein (mRNA), 30 micrograms (0.3 mL dose); Comirnaty® Omicron XBB.1.5 - December 2025
Last updated
28 August 2026